Literature DB >> 1520647

Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients.

P Gibelin1, F Tiger, V Moles, S Bossan, P Blanc, M Baudouy, P Morand.   

Abstract

This open study compared the efficacy and side effects of two dose regimens of intravenous rt-PA initiated before the fifth hour after the onset of myocardial infarction. The first 40 patients (group A) received 1 mg/kg of rt-PA infused over 90 minutes, including a 10-mg initial bolus. The following 41 patients (group B) received 1.5 mg/kg (20-mg initial bolus, 60% over 60 minutes and 40% over 120 minutes). Noninvasive clinical, electrocardiographic, and biochemical parameters of reperfusion were recorded systematically, along with serial measurements of fibrinogen and hemoglobin levels. Coronary arteriography and left ventriculography were performed at the 48th hour or earlier, on an emergency basis, in the absence of signs of reperfusion, or if there were clinical and ECG signs of rethrombosis. Patency of the infarct-related artery (TIMI grades 2 and 3) was achieved in 55% of the group A patients vs. 83% of the group B patients (p less than .01). Twelve emergency coronary arteriographies were performed in each group. No significant difference was observed in the ejection fraction (48% in group A vs. 52% in group B). The peak CPK level was similar in both groups, but the peak occurred earlier in group B (p less than .001). There was no statistically significant difference between the two dose regimens in terms of reduction in fibrinogen or plasminogen levels. Two deaths occurred in group A vs. one death in group B. No cerebrovascular accidents occurred in either group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520647     DOI: 10.1007/bf00054184

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  19 in total

1.  Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens.

Authors:  R W Smalling; R Schumacher; D Morris; K Harder; F Fuentes; R P Valentine; L L Battey; M Merhige; D E Pitts; H A Lieberman
Journal:  J Am Coll Cardiol       Date:  1990-04       Impact factor: 24.094

2.  Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.

Authors:  M Verstraete; A E Arnold; R W Brower; D Collen; D P de Bono; C De Zwaan; R Erbel; W S Hillis; R J Lennane; J Lubsen
Journal:  Am J Cardiol       Date:  1987-08-01       Impact factor: 2.778

3.  Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).

Authors:  K L Neuhaus; U Tebbe; M Gottwik; M A Weber; W Feuerer; W Niederer; W Haerer; F Praetorius; K D Grosser; W Huhmann
Journal:  J Am Coll Cardiol       Date:  1988-09       Impact factor: 24.094

4.  Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.

Authors:  U Tebbe; P Tanswell; E Seifried; W Feuerer; K H Scholz; K S Herrmann
Journal:  Am J Cardiol       Date:  1989-09-01       Impact factor: 2.778

5.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

6.  The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty.

Authors:  E Passamani; M Hodges; M Herman; R Grose; B Chaitman; W Rogers; S Forman; M Terrin; G Knatterud; T Robertson
Journal:  J Am Coll Cardiol       Date:  1987-11       Impact factor: 24.094

7.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.

Authors:  F Van de Werf; A E Arnold
Journal:  BMJ       Date:  1988-11-26

8.  Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.

Authors:  B Magnani
Journal:  J Am Coll Cardiol       Date:  1989-01       Impact factor: 24.094

9.  Follow-up after coronary arterial reperfusion with intravenous streptokinase in relation to residual myocardial infarct artery narrowings.

Authors:  R Schröder; H Vöhringer; T Linderer; G Biamino; T Brüggemann; E V Leitner
Journal:  Am J Cardiol       Date:  1985-02-01       Impact factor: 2.778

10.  Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group.

Authors: 
Journal:  JAMA       Date:  1988-11-18       Impact factor: 56.272

View more
  2 in total

Review 1.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 2.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.